We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The number of patent settlements between brand and generic drugmakers has increased in recent years, and the agreements are being completed without payments from the brand to the generic in exchange for the generic's commitment not to market the product, according to a new federal study.
Federal securities class action lawsuits involving product liability claims, such as those filed against Merck and Pfizer, may represent a growing trend in the class action field, according to a new report.
A series of upcoming town hall meetings on proposals to reform the U.S. patent system, including legislation that would allow firms to challenge the validity of patents at their issuance rather than in the courts will include pharmaceutical executives among the featured speakers.
Patent settlements between brand and generic drugmakers have increased in recent years, and the agreements are being completed without payments from the brand to the generic in exchange for the generic’s commitment not to market the product, according to a new federal study.
The brand industry will have strong voice in a series of upcoming meetings on proposals to reform the U.S. patent system, including legislation that would allow firms to challenge the validity of patents at their issuance rather than in the courts.
Pharmaceutical executives are among the featured speakers at a series of upcoming town hall meetings on proposals to reform the U.S. patent system, including legislation that would allow firms to challenge the validity of patents at their issuance rather than in the courts.
The FTC will allow biotechnology company Genzyme’s proposed $1 billion acquisition of Ilex Oncology to proceed as long as the companies surrender the rights to a key organ transplant drug, according to the terms of a consent order.
Generic firm Barr Laboratories has filed an abbreviated new drug application (ANDA) with a paragraph IV certification for a generic version of Actiq — even though the company already has been licensed by brand drugmaker Cephalon to manufacture and market the product.
The FTC has charged three related dietary supplement manufacturers and their corporate officers with producing deceptive direct mail and internet advertisements for weight-loss and erectile-dysfunction products.
The FTC should launch an inquiry to determine if price gouging is pervasive for U.S. flu vaccine stocks and whether there is any justification for price increases for the vaccine, according to the leaders of the House Government Reform Committee.